New Research Sheds Light on Factors Influencing Medical Scheme Enrolment Decisions

By Staff Writer

July 24, 2023

The Council for Medical Schemes recently published an insightful study in the American Journal of Biomedical Science and Research titled ‘Profiling Dependants Joining Medical Schemes: An Analysis of Factors Influencing Enrolment Decisions.’

The study provides a fresh perspective in the ongoing debate between ‘medical aids’ and ‘cheap medical aid.’ From 2017 to 2021, an average of 1.1 million new dependants joined medical schemes each year, with newborns making up 23% and children under five accounting for 35%.

The authors suggest that by understanding enrolment decisions, medical schemes can tailor their strategies to the specific needs of dependants, potentially leading to higher enrolment rates and improved healthcare outcomes.

Enrolment in a medical scheme is a complex process influenced by multiple factors, including affordability, age, and healthcare needs.

Interestingly, in 2019, medical schemes collectively saw a high number of new dependants join the scheme at 1.3 million. However, in 2021, this number dropped to 622,000, likely due to the economic impact of COVID-19.

Closed schemes tend to enrol more new dependants below the age of 5, while open schemes typically enrol more beneficiaries aged 60 years.

The study also revealed that costs, availability of cost-sharing mechanisms, and financial incentives influence dependants’ decision to enrol in medical schemes.

To expand health insurance coverage, interventions should prioritize the healthcare needs of children and the elderly.

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.